来自MSN1 天
Optinose Reports $22.4 Million in Preliminary Q4 Revenue for XHANCE
YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced preliminary unaudited net product revenue of $22.4 million for the fourth ...
Healthline13 天
Xhance Interactions: Alcohol, Medications, and Others
Xhance (fluticasone propionate) is a prescription nasal spray. It’s used to treat nasal and sinus inflammation with or without nasal polyps in adults. This drug can interact with other ...
Investing4 天
Optinose reports steady Q4 revenue growth
In light of these financial results, OptiNose revised its 2024 sales forecast for Xhance, its nasal spray treatment, to a range of $75 million to $79 million. Despite this adjustment, the company ...
Nasdaq4 天
Optinose Reports Q4 XHANCE Net Product Revenue; Sees Continued Growth In Year Ahead
(RTTNews) - Optinose, Inc. (OPTN), a pharmaceutical company focused on ear, nose and throat or ENT and allergy, announced Wednesday preliminary XHANCE (fluticasone propionate) net product revenue ...
Investing4 天
Optinose reports steady Q4 revenue growth
In light of these financial results, OptiNose revised its 2024 sales forecast for Xhance, its nasal spray treatment, to a range of $75 million to $79 million. Despite this adjustment, the company ...
Investing16 天
Optinose stock price target raised at H.C. Wainwright given reverse split
has seen its profile rise with the development of XHANCE, a corticosteroid drug-device combination nasal spray. XHANCE is the first and only approved treatment for patients with chronic ...